

## **Supplementary Material for**

# **Comparison of Efficacy and Safety Between Anterior Cisterna and High Cervical Intrathecal Drug Delivery for Craniofacial Cancer Pain: A Multi-Center Retrospective Cohort Study**

**Authors:** Qin Li<sup>1\*</sup>, Deshan Li<sup>2\*</sup>, Qiju Li<sup>3\*</sup>, Zheng Zou<sup>7\*</sup>, Huaiming Wang<sup>1</sup>, Xin Min<sup>4</sup>, Yu Wang<sup>5</sup>, Jiang Zou<sup>6#</sup>, Pengjiu Feng<sup>7#</sup>, Aimin Zhang<sup>1#</sup>

<sup>1</sup> Department of Anesthesiology and Pain Medicine, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610041, China.

<sup>2</sup> Department of Interventional Therapy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science and Technology of China, Chengdu 610041, China.

<sup>3</sup> Department of Oncology, Chengdu Xinhua Hospital, Xinhua Hospital Affiliated to North Sichuan Medical College, Chengdu 610051, China.

<sup>4</sup> Department of Anesthesiology and Pain, The People's Hospital of Leshan, Leshan 614099, China.

<sup>5</sup> Department of Pain Medicine, The Third People's Hospital of Chengdu, Chengdu 610041, China.

<sup>6</sup> Sichuan Women's and Children's Hospital/Women's and Children's Hospital, Chengdu Medical College, Chengdu 610031, China.

<sup>7</sup> Department of Pain Medicine, The Third Affiliated Hospital of Guangxi University of Chinese Medicine, Liuzhou traditional Chinese medical hospital, Liuzhou 545001, China.

\*Contributed equally to this paper as co-first authors.

#Contributed equally to this paper as co-corresponding authors.

## **Corresponding Author:**

Aimin Zhang, MD, Department of Anesthesiology and Pain Medicine, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, University of Electronic Science

and Technology of China, Chengdu 610041, China

Email: zhangaimin@scszlzyy.org.cn

**This file includes:**

- Supplementary Table S1: Baseline Characteristics of Included vs. Excluded Patients
- Supplementary Figure S1: Propensity score distribution before and after matching

**Supplementary Table S1. *Baseline Characteristics of Included vs. Excluded Patients***

| Characteristic                   | Included Patients<br>(n=108) | Excluded Patients<br>(n=48) | <i>P</i> value |
|----------------------------------|------------------------------|-----------------------------|----------------|
| <b>Demographics</b>              |                              |                             |                |
| Age, years                       | 58.7 ± 11.3                  | 57.9 ± 12.1                 | 0.672          |
| Female, n (%)                    | 47 (43.5)                    | 22 (45.8)                   | 0.783          |
| BMI, kg/m <sup>2</sup>           | 22.3 ± 3.9                   | 21.8 ± 4.2                  | 0.445          |
| <b>Disease Characteristics</b>   |                              |                             |                |
| Pain duration, months            | 6.2 [3.2,11.5]               | 5.8 [2.9,10.7]              | 0.588          |
| Metastatic cancer, n (%)         | 83 (76.9)                    | 34 (70.8)                   | 0.412          |
| <b>Pain Characteristics</b>      |                              |                             |                |
| Baseline NRS score               | 8.3 ± 1.2                    | 8.1 ± 1.4                   | 0.334          |
| Breakthrough pain episodes/day   | 3.2 [2.0,5.3]                | 3.4 [2.2,5.8]               | 0.512          |
| Breakthrough pain NRS            | 7.5 ± 1.4                    | 7.7 ± 1.6                   | 0.423          |
| <b>Pre-operative MED, mg/day</b> | 185 [125,315]                | 190 [130,310]               | 0.845          |
| <b>Catheter Approach, n (%)</b>  |                              |                             | 0.621          |
| - Anterior Cisterna (AC)         | 33 (30.6)                    | 12 (25.0)                   |                |
| - High Cervical (HC)             | 75 (69.4)                    | 36 (75.0)                   |                |

Data presented as mean ± SD, median [IQR], or n (%). MED = morphine equivalent dose.

**Supplementary Figure S1** *Propensity score distribution before and after matching*

